1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Exploratory/Developmental Cooperative Agreement Phase I (UH2) is a grant from the National Institutes of Health (NIH) that funds the development of new research activities in categorical program areas. The mechanism supports exploratory and developmental work with awards generally restricted in level of support and duration, providing up to $275,000 over two years.
The UH2 mechanism operates under a cooperative agreement structure, meaning NIH maintains substantial involvement in the research. Standard NIH application due dates apply. Note that beginning with applications for Advisory Council Review in January 2027, NIH will no longer accept AIDS-related applications due May 25, 2026 or later.
Eligible applicants include nonprofits, universities, state and local governments, and for-profit organizations.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Exploratory/Developmental Cooperative Agreement Phase I (UH2) | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health Exploratory/Developmental Cooperative Agreement Phase I (UH2) To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.)
Exploratory/Developmental Cooperative Agreement Phase I Use the Explore NIH Grant Opportunities tool to search Grants. gov. Ready to develop your application? Learn from a step-by-step guide.
Standard Due Dates apply. AIDS and AIDS-Related Applications Beginning with applications for Advisory Council Review in January 2027 (i.e., application due dates on or after May 25, 2026), NIH will no longer accept applications submitted on dedicated AIDS application due dates.
( NOT-OD-26-029 ) Standard Application Due Dates (when applicable) Participating Funding Organizations Each funding opportunity specifies the participating organizations. Applications must fit within the mission of at least one participating funding organization and meet all opportunity-specific requirements. The following funding organizations participate on at least one active funding opportunity.
National Cancer Institute For technical issues E-mail OER Webmaster
According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments, For-profit organizations, Government institutions. Confirm the full requirements in the official notice before applying.
The current listing shows up to $275,000 over two years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Exploratory/Developmental Cooperative Agreement Phase I (UH2) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article